BioNTech SE
BNTX
$101.81
$3.053.09%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 1.27B | 1.37B | 138.52M | 203.66M | 1.59B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.27B | 1.37B | 138.52M | 203.66M | 1.59B |
| Cost of Revenue | 259.56M | 196.68M | 64.36M | 64.16M | 192.82M |
| Gross Profit | 1.01B | 1.17B | 74.16M | 139.50M | 1.40B |
| SG&A Expenses | 140.81M | 165.46M | 197.83M | 143.95M | 153.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 47.01M | 378.41M | 282.32M | -9.23M | -458.30M |
| Total Operating Expenses | 1.10B | 1.35B | 1.17B | 749.81M | 509.76M |
| Operating Income | 168.96M | 22.98M | -1.04B | -546.16M | 1.08B |
| Income Before Tax | 321.07M | 174.47M | -867.31M | -360.20M | 713.99M |
| Income Tax Expenses | 44.45M | -43.32M | 2.15M | -18.13M | 221.02M |
| Earnings from Continuing Operations | 276.62M | 217.79M | -869.46M | -342.07M | 492.97M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 276.62M | 217.79M | -869.46M | -342.07M | 492.97M |
| EBIT | 168.96M | 22.98M | -1.04B | -546.16M | 1.08B |
| EBITDA | 296.66M | 71.79M | -981.51M | -504.58M | 1.12B |
| EPS Basic | 1.15 | 0.90 | -3.62 | -1.42 | 2.06 |
| Normalized Basic EPS | 0.92 | 0.57 | -2.19 | -0.88 | 1.90 |
| EPS Diluted | 1.15 | 0.89 | -3.62 | -1.42 | 2.04 |
| Normalized Diluted EPS | 0.92 | 0.56 | -2.19 | -0.88 | 1.89 |
| Average Basic Shares Outstanding | 240.28M | 241.59M | 240.42M | 240.53M | 239.74M |
| Average Diluted Shares Outstanding | 240.28M | 244.57M | 240.42M | 240.53M | 241.00M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |